MFIM
LCTX icon

Mesirow Financial Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Mesirow Financial Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.3K Sell
30,000
-500
-2% -$691 ﹤0.01% 525
2026
Q1 		$48.2K Buy
+30,500
New +$51.4K ﹤0.01% 513
2025
Q2 		– Sell
-20,000
Closed -$9.03K – 580
2025
Q1 		$9.03K Sell
20,000
-1
-0% -$1 ﹤0.01% 588
2024
Q4 		$10.1K Buy
+20,001
New +$14.7K ﹤0.01% 594

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $136M AUM 18.56% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
BWCS
Beirne Wealth Consulting Services Shelton, Connecticut $503M AUM 27.98% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Mesirow Financial Investment Management's LCTX Position: Q2 2026 in Review

Mesirow Financial Investment Management reduced its Lineage Cell Therapeutics (LCTX) stake by 1.6% in Q2 2026, selling an estimated $691 and leaving 30,000 shares worth $39.3K. The position accounts for ﹤0.01% of the portfolio, ranked #525.

Mesirow Financial Investment Management first reported a position in LCTX in Q4 2024 and has held it in 4 quarters since. The position peaked at $48.2K in Q1 2026. 32 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Mesirow Financial Investment Management held 30,000 shares of Lineage Cell Therapeutics worth $39.3K as of Q2 2026.
  • Mesirow Financial Investment Management sold 500 Lineage Cell Therapeutics shares in Q2 2026, an estimated $691.
  • Lineage Cell Therapeutics made up ﹤0.01% of Mesirow Financial Investment Management's portfolio in Q2 2026, its #525 holding.
  • Mesirow Financial Investment Management first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Mesirow Financial Investment Management's Lineage Cell Therapeutics position peaked at $48.2K in Q1 2026.
  • 32 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.